Breast Cancer Clinical Trial
Official title:
Cancer Information Service Research Consortium: Years 2006-2011 Program Narrative and Overview
RATIONALE: A multimedia educational program may help patients with newly diagnosed prostate
cancer and breast cancer reduce distress, make informed treatment decisions, and improve
quality of life.
PURPOSE: This randomized clinical trial is studying how well a multimedia educational
program works in patients with early-stage prostate cancer or breast cancer.
OBJECTIVES:
Primary
- Determine whether an innovative multimedia educational program will help newly
diagnosed prostate (project 1) and breast (project 2) cancer patients prepare for their
journey as cancer patients, promote informed treatment decision-making and reduce
cancer-specific distress, and among breast cancer patients at re-entry, facilitate an
informed re-entry transition to cancer survivorship and reduce cancer-specific distress
(project 3).
- Determine whether having Cancer Information Service (CIS) Information Specialists make
a scheduled telephone callback to callers in project 3 will augment and support use of
the CIS Research Consortium (CISRC) multimedia educational programs and further enhance
the study outcomes examined in this program of research.
- Determine whether the hypothesized mediational variables account for significant
intervention effects in each of the three component projects.
- Examine potential moderator variables to assess potential differences in intervention
efficacy by selected subgroups (e.g., age, education) within each component project.
- Conduct an in-depth tracking study of utilization patterns for a detailed description
of different patterns of use, as well as elucidating those components or modules within
the program that had differential utilization by participants.
- Assist the CIS and other similar cancer information systems in disseminating one or
more of the CISRC interventions should they prove effective in this program of
research.
Secondary
- Conduct secondary analyses across projects (i.e., perceived need for and benefit from
the CISRC interventions and intervention efficacy across three high priority cancer
patient populations) that will be made possible by the use of a common theoretical
framework, the same or similar intervention and research design across projects, and a
common set of endpoints.
OUTLINE: This is a multicenter study.
Patients are assessed by demographic questions and a baseline interview conducted by Cancer
Information Service (CIS) Information Specialists.
Patients are randomized to 1 of 3 intervention groups:
- Group 1: Patients receive a mailing containing standard CIS print materials. In project
1, patients receive " Treatment Choices for Men with Early-Stage Prostate Cancer" and
"What You Need to Know About Prostate Cancer". In project 2, patients receive "What You
Need to Know About Breast Cancer" and "Surgery Choices for Women with Early-Stage
Breast Cancer". In project 3, patients receive "Facing Forward: Life After Cancer
Treatment" and "What You Need to Know About Breast Cancer".
- Group 2: Patients receive mailings appropriate to their project as in group 1. Patients
also receive the multimedia program via the Internet or CD-ROM.
- Group 3: In project 3 only, patients receive mailings appropriate to their project as
in group 1 and the multimedia program as in group 2. Patients also receive a CIS
callback intervention at 10-14 days from trained Information Specialists from the CIS.
After completion of study therapy, patients are followed at 2 and 9 months.
;
Intervention Model: Single Group Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |